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Phytoestrogens are a group of plant-derived natural prod-
ucts which include lignans, isoflavones, coumestans, and
resorcyclic acid lactones. Dietary consumption of lignans
and isoflavones has been postulated to play a role in the
protection of humans against development of coronary heart
disease (1). In order for some of these plant-derived com-
pounds to be biologically active, they must be modified by
intestinal bacteria. For instance, isoflavones, including bio-
chanin A, are found in soybeans and chick peas, and have
direct biological activity, whereas other isoflavones are
modified by the gut flora to produce biologically active
compounds such as genistein. Lignans are found in high
concentrations in oil seeds and cereals. The most abundant
mammalian lignan is enterolactone, which is dependent on
the intestinal bacteria for its synthesis from the plant
precursor. Flavanoids are often found in a glycoside form.
There are structural similarities between phytoestrogens and
17b-estradiol (2). It is well established that 17b-estradiol
has vasodilating properties (3).
There is growing evidence from epidemiologic studies
that consumption of phytoestrogens has a beneficial effect
on the risk of acute coronary events. Vanharanta et al. (4)
recently reported a case-control study relating the serum
enterolactone concentration (a marker for phytoestrogen
dietary consumption) with risk for acute coronary events
in men. Men in the highest enterolactone quartile had a
65% lower risk than did men in the lowest quartile for
acute coronary events over 7.7 years (4). The investigators
concluded that dietary consumption of plant-derived
fiber-rich food lowers the risk for coronary heart disease
substantially.
In this issue of Journal, Figtree et al. (5) provide useful
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and novel insights into the mechanism of action of phy-
toestrogens on coronary artery vascular tone. They use the
combination of classic vascular smooth muscle contractility
studies, cardiac myocyte studies of calcium current and
contractility and human studies to define relevant serum
concentrations of a phytoestrogen-derived product in
plasma. These authors clearly demonstrate that several
phytoestrogens, including biochanin A and genistein, relax
precontracted rabbit coronary artery rings. Through a series
of carefully designed and conducted experiments, they
exclude several candidate mechanisms of action for the
vasodilator effects. The highly efficacious vasodilator effects
of genistein are not dependent on nitric oxide and are
independent of endothelium. This is of therapeutic interest,
as conceivably these compounds might be used in patients
with diseased and dysfunctional endothelium. They also
demonstrate that the vasodilator effects are not dependent
on the estrogen receptor ER-alpha, although they cannot
exclude an effect of ER-beta. The authors establish that the
isoflavone, genistein, appears to function as a calcium
channel blocker in vascular smooth muscle and in cardiac
myocytes. The pharmacologic effects of genistein in vascular
smooth muscle are as one might expect from an organic
calcium channel blocker. In isolated guinea pig myocytes,
genistein decreases calcium current and cell contractility in
a concentration-dependent manner. Of considerable impor-
tance, the plasma concentration found in normal humans
after consuming a soy liquid supplement (Supro), 2 mmol/
liter, is associated with significant inhibition of the calcium
current in myocytes. Thus, concentrations achievable in
humans taking phytoestrogen dietary supplements corre-
spond with important biological effects in vitro.
Exactly how does genistein block the L-type calcium
channel? Additional, more detailed molecular pharmaco-
logic and biophysical work will need to be done to define
this more fully. The work by Figtree et al. (5) reported in
this issue of the Journal begins to explore the mechanism.
Genistein is a tyrosine kinase antagonist. However, it is
unlikely that this is important for its calcium channel
blocking effects. Of note, the precursor of genistein, bio-
chanin A (which is not a tyrosine kinase antagonist), is a
more potent inhibitor of vascular smooth muscle tone than
is genistein.
Phytoestrogens hold therapeutic potential for cardiovas-
cular disease. Of note, in the recent study by Vanharanta et
al. (4), there appeared to be an association between in-
creased dietary consumption of phytoestrogens (using the
serum enterolactone concentration as a marker) and lower
systolic and diastolic blood pressure. Are phytoestrogens
“natural” calcium channel blockers that may have therapeu-
tic benefit for coronary artery disease and hypertension?
Possibly. However, caution is warranted in adopting phy-
toestrogens as home remedies. Synthesis of some mamma-
lian phytoestrogens is dependent on gut flora, and synthesis
is abolished for three weeks by a course of oral antibiotics.
Thus, the bioavailability of phytoestrogens will likely be
highly variable. It is not a wise therapeutic strategy for
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hypertension or angina to have the effect of a natural
product (a phytoestrogen) abolished when a patient takes a
course of antibiotics for a urinary tract infection. Moreover,
there may be important interactions with other drugs,
including warfarin. At this time, we do not know which
member(s) of the phytoestrogens may have the greatest
potential for therapeutic benefit.
Will phytoestrogens be the “vascular glycosides” of the
21st century, just as digitalis glycoside extracts of the
foxglove leaf were the “cardiac glycosides” of the past two
centuries? Physicians no longer prescribe the pill, digitalis
leaf, with its host of glycosides possessing varying therapeu-
tic and toxic effects. It is likely that our patients will be best
served, just as in the case of cardiac glycosides, by investi-
gators carefully defining, purifying, standardizing, and de-
termining the mechanism of action of the plant-derived
natural products. Phytoestrogens do have the potential to be
useful agents for prevention and treatment of vascular
disease, but we have a great deal to learn about their safe and
effective use.
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